The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes despite the SP I feel far more bullish, the new 737 deal gives me some backstop confidence in a negative scenario for 1801, however 1801 in reality is deep into 1a (possibly complete) positive news on the results open the chance of early deals whilst 1b is in flight and richer deals at the end of 1b. For me far more positive than negative signs. Might buy more but definately not considering selling at this time GLA
Hi sflf - I am not going to fall for your negative thread header I'm afraid. Out of interest, what do you call heavily invested and could you explain why you are somewhat concerned.
I'm heavily invested and somewhat concerned.........
Just to emphasise the point - this article written in 2021 sums up what happens and why investors can often buy at the wrong time.
https://www.investopedia.com/trading/market-cycles-key-maximum-returns/
Whether he is or isn't is irrelevant. Is anything he has said actually wrong?
1.
Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential - They have an allosteric TYK2i...
https://finance.yahoo.com/news/myrobalan-therapeutics-completes-series-financing-114500871.html
2. J.P. Morgan Day Three: Biogen Still Shopping For Deals, Sanofi Explains Its View On Oncology
10 Jan 2024 - Takeda To Take TYK2 Inhibitor Into IBD At High Dose
https://scrip.citeline.com/SC149610/JP-Morgan-Day-Three-Biogen-Still-Shopping-For-Deals-Sanofi-Explains-Its-View-On-Oncology
3. Science heavy, but a good read: New and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis:
https://www.preprints.org/manuscript/202401.0800/v1
direct .pdf: https://www.preprints.org/manuscript/202401.0800/v1/download
4. https://www.dermatologytimes.com/view/hello-2024-what-surprises-are-in-store-for-dermatology-this-year-
5. Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy:
https://link.springer.com/article/10.1007/s00011-023-01833-w#Sec21
ATB
Still all good here atm. Sareum is in a much stronger position despite the drag on the sp which, by the way, is being replicated across AIM.
Sareum has been further de-risked and Ph1a results will further de-risk us if good.
Institutional Investors would probably have offered a worse deal than RF such is their greed and opportunism.
Follow the news.
Boundless Bio raised $100 Million 6 months ago. i.e. if it they have licenced SRA737 / CCT-245737 then they clearly have the ability to raise funds to progress drug candidates. Interesting.....
https://synapse.patsnap.com/news-detail/a9d660c9-96a5-3720-8c71-f0babbb48392-boundless-bio-announces-100-million-oversubscribed-series-c-financing-co-led-by-leaps-by-bayer-and-ra-capital-management-to-advance-the-first-ecdna-directed-therapies-ecdtx-for-patients-with-oncogene-amplified-cancer
Good luck, Brighty
OK regarding Boundless Bio and HotblackDesiato's post this is what I have found out. In summary, SRA737 can now also be found as CCT-245737 when searching for Boundless Bio, see the link below:
https://synapse.patsnap.com/drug/32bdb04583b043818d7808672c8fa1c6#research
Of particular interest is this piece of information:
Drug Type
Small molecule drug
Synonyms
PNT-737,
SRA-737,
SRA737
+ [1]
Target
Chk1(Checkpoint kinase 1)
Mechanism
Chk1 inhibitors(Checkpoint kinase 1 inhibitors)
Therapeutic Areas
Neoplasms,
Digestive System Disorders,
Endocrinology and Metabolic Disease
+ [4]
Active Indication
Ovarian Cancer,
Sarcoma,
Small Cell Lung Cancer
+ [13]
Inactive Indication
-
Originator Organization
Sareum Holdings Plc
Sareum Holdings Plc
Active Organization
Sareum Ltd.
Sareum Ltd.
Sierra Oncology, Inc.
Sierra Oncology, Inc.
Institute Of Cancer Research
Institute Of Cancer Research
Inactive Organization
Sareum Holdings Plc
Sareum Holdings Plc
Drug Highest Phase
Phase 2
Good luck, Brighty
Sflf isn’t invested here.
WOW Celtic, did you go to school? You need to work on your grammar and language fella.
Sflf.
Pragmatic summation but be prepared for some heckling from the "owners" of this BB
Good morning HBD,
An excellent post, I recall the discussions here way back regarding Christian Hassiq and indeed Triparna Sen being named on an SRA737 patent, and the move to Boundless Bio for Hassig; it certainly piqued some interest at the time.
As you can probably imagine, I have several pages bookmarked regarding Hassig, his patents and movements as he is IMO the most obvious potential suitor to take SRA737 forwards having seen the potential whilst at Sierra Oncology.
These things take time, but its certainly interesting to dig and delve, looking for snippets and leads. One must keep the mind sharp and trained as much as the body - (I much prefer this to crosswords & sudoku's so its a win!)
As a side note, and as you are clearly aware, looking at patents can really provide an insight into the science and potential direction for companies - doing so has provided very good early "ins" when investing in the past - sew up the intellectual property and protect the potential assets early and a company is already doing more than many of their competitors. Something I feel Sareum has been very good at! "News flow" & creating a buzz, not so much!
Thanks again for your excellent posts
ATVB
So the small lift from the 737 was was short lived . That gain has reversed and we're basically back to the same low levels. It seems there's no appetite for the stock on the open market with private investors. And no institutional investors were interested in the stock either as a placing was taken off the table in favour of the deal that was done.
This will now take very significant news, with a clear path to monetize the assets, to move the share price north. Here's praying that news comes soon.
Strap in, I think it's going to be a bumpy ride.
Time will tell. Hope it comes good. Bye all
You are right Lazarus .. it hasn’t been all bad here although the current downward trend is baffling given recent news and progress on 1801 .. it makes no sense at all. The rise in 2021 gave all LTH the chance to do a bit of top slicing; the gain I was lucky enough to nail down when I sold 1/3 in the summer of 2021 means even if SAR drops to 20p I will have still doubled my initial investment made in 2011; however I want to see it where it belongs which is up over £2.50 and beyond not least because there are people here who first invested in 2021.
Thanks for your best wishes cfh.
Surfie - A Freudian slip surely - you instead of we?
Sienna - It hasn’t all been down in the doldrums - Sareum has had a few good periods where we have all made good money.
Believe the science and follow the news. Otherwise why would you be here
Https://medcitynews.com/2024/01/gsk-cancer-jpm-targeted-oncology-drugs/
Vented a similar post possibly a couple of years ago.This company has got sweet FA.Poster presentations and conferences.Lambasted at the time,when the sp was much higher.Good luck remainers,you're gonna need it.From a former pharmaceutical research chemist.
OMG... you couldn't make it up over 75p down to 57p so far this year. An 8% drop today and still the faithful bang the "believe in the science" drum. Even Afham has buggered off! I'm invested, or at least what I have left is still invested but this company is a joke.
A nice range of investors, Boundless Bios have.
Ridiculous post by you Siennaj, was it tarot cards or a crystal ball. Blimey.
Siennaj, disagree with some of your post. Just look whats happening here, i agree timelines get consistently broken but nothing wrong with the science to date, thats more relevant than dates
I wonder of Afham has become disillusioned with the extremely long wait here for anything to happen. I'm not a lth but I understand a good number here have been here for between 10 and 15 years and to see the price nearing 50p which is 1p before the consolidation must.be very disheartening. I've held Sar for about 3 years now. I've sold out as the price keeps dropping and trying elsewhere. Essentially sar haven't sold anything and what was supposed to b products that the big boys would b scrapping over appears not to b happening. I only hold 2000 shares now but to see this continue to decline us sad and I'm glad I was never involved over a decade ago. Such a waste of time money and hope sad to say
Ahfam, hopefully he’s received a short term ban. Yes he was a feisty character, but he was only protecting his investment against the crap that was posted. If he’s banned, they should re in state him.